**Exhibit10.30**

**EXTENSION AND AMENDMENTTO PROMOTION ANDCOOPERATION AGREEMENT**

WHEREAS

CollaGenex Pharmaceuticals Inc., a corporationestablished under the laws of Delaware with offices at 41 University Drive,Newtown, PA 18940, (“CollaGenex”), and

Primus Pharmaceuticals, Inc. a company having itsprincipal place of business at 4725 North Scottsdale Road, Suite 200,Scottsdale AZ 85251 (“Primus”)

Entered into a Promotion and Cooperation Agreementdated as of June 6, 2005 (the “Agreement”); and

WHEREAS, after discussions CollaGenex and Primus wishto extend and amend the terms of the Agreement;

NOW THEREFORE CollaGenex and Primus agree as follows:

# 1.             **Sales Targets**.  TheSales Targets and the time periods to which they relate in Section 3(g) of theAgreement are amended by revising Section 3(g) to read as follows:

Sales Targets. CollaGenex shall achieve at least the following combined levels of salesof the Products in the Territory, calculated with reference to prescriptionsfilled data available from industry standard and commercially available sourcesapproved by the Steering Committee and assuming sales at Net Sales Price (asdefined on Exhibit D), during the following time periods:

| Between 7/1/06 and 12/31/06 |   | $1,600,000 |
|-----------------------------|--------|------------|
| Between 1/1/07 and 12/31/07 |   | $3,600,000 |

 

Between 1/1/08 and 12/31/08and for any annual renewal periods thereafter, the Steering Committee shall setsales targets.

# 2.             **Marketing Expenses andAllocation of Marketing Expenses**.  Sample expense shall betreated as a marketing expense, to be paid initially by Primus and then madepart of the quarterly adjustment process conducted by the Steering Committeesuch that marketing expenses are allocated between the parties, 60% to be paidby CollaGenex and 40% to be paid by Primus. Accordingly,

## 2.1           Section 4(f) of the Agreement isamended to read as follows:

Samples All samples shall be purchased by Primusand subsequently supplied to CollaGenex in accordance with the procedureoutlined in Exhibit B.  Primus willcontinually work to decrease the overall cost of samples.  The Steering Committee will define a sampleplan to determine allocations of samples and to minimize cost of samples.  Primus will be responsible for submittingsample forecasts to their manufacturer and assuring that samples are availableto support the sample plan 

----

determined by the SteeringCommittee and based on the sample forecasts provided by CollaGenex per Section3(e). [the remainder of original Section 4(f) is deleted]

## 2.2           The final paragraphs identified as “Payment:”and “Submission of PO’s:” on Exhibit B of the Agreement are amended to read asfollows:

|        | Payment:           | Primus shall make all payments relating to sample  POs on such terms as it  shall agree with its sample manufacturer.                                                  |
|--------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | Submission of POs: | All PO’s shall be  submitted to sample manufacturer by Primus in amounts consistent with the  marketing budget, or as otherwise agreed by the Steering Committee. |

 

## 2.3           Section 8(b)(i) of the Agreement isamended to read as follows:

### (i)            If CollaGenex does not achieve thesales target for the measurement period in each calendar year (i.e.,7/1/06-12/31/06, 1/1/07-12/31/07 and 1/1/08-12/31/08) referenced in 3(g) andnotice is sent by Primus on or before the end of the third month following themeasurement period.

Sections 8(b) (ii) and 8 (b) (iv) of the Agreement aredeleted.

## 2.4           Sections 5(b) 5(c) and 5(d) of theAgreement are amended to read as follows:

#### (b)                                 Marketing Budget.  Themarketing budget shall be agreed to by the Steering Committee and not exceed20% of net sales for the most recent quarter annualized unless otherwiseauthorized by the Parties.  As acomponent of the marketing budget, the Parties agree total annual lunch &learn expenses allocated to the Products will have a budget not to exceed$187,500 (calculated as 12.5% of Collagenex’s 2007 total Company lunch &learn budget).  On at least an annualbasis, the Steering Committee will perform a quantitative analysis of the salesand marketing support necessary to deliver the sales volumes committed perSection 3(g).  Components of the analysisshall include (but not be limited to) samples, lunch and learn costs,nonpersonal promotion and call coverage. Using this analysis, the Parties agree to adjust marketing spending andsales coverage as needed to deliver desired sales volumes while managingprofitability.

#### (c)                                  Allocation of Marketing Expenses.  AllProduct specific incremental Marketing Expenses (including samples and samplefulfillment to both physicians and field sales reps as agreed by the SteeringCommittee, but excluding any other matters specifically made the financialresponsibility of one Party or the other under this Agreement) shall be paid for 40% byPrimus and 60% by CollaGenex.  Pre-existingexpenses of either Party that are not specific to the generation ofprescriptions for the Products, such as expenses related to specificfoundations and sponsorships not directly associated with the Products and theacquisition of non-Product 

2

----

####                                                 specific marketdata from IMS, Verispan or an industry standard commercially available database approved by the Steering Committee, shall not be considered to beallocable marketing expenses.

#### (d)                                 Manner of Payment of Marketing Expenses. Each Party shall inform the Steering Committee quarterly of themarketing expenses it has incurred during the preceding quarter, and theSteering Committee shall calculate an appropriate adjustment to be applied tothe next payment of Regular Consideration to the extent necessary to effect the40/60 split referenced above.

# 3.             **Term of Agreement**.  TheAgreement is extended until December 31, 2008. Accordingly Section 7(a) is amended to read as follows:

#### (a)                                  Initial Term. This Agreement shall become effective on the Effective Date and unlessotherwise terminated or renewed pursuant to its terms, shall have an initialterm until December 31, 2008 (the “Initial Term”).

# 4.             **Other Provisions**.  Allother provisions of the Agreement shall remain in full force and effect.

This Extension andAmendment is executed in original counterparts on the 30th day of October, 2006by:
| CollaGenex Pharmaceuticals, Inc.  |   | Primus Pharmaceuticals, Inc. |
|-----------------------------------|--------|------------------------------|
|                              |   |                         |
| By:  /s/  Andrew K.W. Powell |   | By: /s/ J.D. Weir            |
|                              |   |                         |
| Title: Secretary                  |   | Title: CEO                   |

 

3

----